

MIRAGEN THERAPEUTICS, INC.  
Form SC 13D  
February 23, 2017

---

**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**SCHEDULE 13D**

(Rule 13d-101)

**INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a)  
AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)**

(Amendment No. )\*

---

**MIRAGEN THERAPEUTICS, INC.**

(Name of Issuer)

**COMMON STOCK, \$0.001 PAR VALUE PER SHARE**

(Title of Class of Securities)

**60463E103**

(CUSIP Number)

Edgar Filing: MIRAGEN THERAPEUTICS, INC. - Form SC 13D

Accomplice

Attention: Frank Castellucci

25 First Street

Suite 303

Cambridge, MA 02141

(617) 588-2600

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 13, 2017

(Date of Event which Requires Filing of this Statement)

\_\_\_\_\_

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d 1(e), 240.13d 1(f) or 240.13d 1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

\_\_\_\_\_

\_\_\_\_\_

1.	Names of Reporting Persons.  I.R.S. Identification Nos. of above persons (entities only)  <b>ATLAS VENTURE FUND VII, L.P.</b>	
2.	Check the Appropriate Box if a Member of a Group (See Instructions)  (a) <input type="radio"/> (b) <input checked="" type="radio"/>	
3.	SEC Use Only	
4.	Source of Funds (See Instructions)  OO	
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)  <input type="radio"/>	
6.	Citizenship or Place of Organization  Delaware	
Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power  0
	8.	Shared Voting Power  3,142,580
	9.	Sole Dispositive Power

Edgar Filing: MIRAGEN THERAPEUTICS, INC. - Form SC 13D

		0
	10.	Shared Dispositive Power
		3,142,580
11.	Aggregate Amount Beneficially Owned by Each Reporting Person	
		3,142,580
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)	
		0
13.	Percent of Class Represented by Amount in Row (11)	
		14.8%*
14.	Type of Reporting Person (See Instructions)	
		PN

\* Calculated based upon the approximately 21.3 million shares of the common stock reported by the Issuer to be issued and outstanding as of February 13, 2017, in its Current Report on Form 8-K, as filed with the Securities and Exchange Commission on February 13, 2017.

1.	Names of Reporting Persons.  I.R.S. Identification Nos. of above persons (entities only)  <b>ATLAS VENTURE ASSOCIATES VII, L.P.</b>	
2.	Check the Appropriate Box if a Member of a Group (See Instructions)  (a) <input type="radio"/> (b) <input checked="" type="radio"/>	
3.	SEC Use Only	
4.	Source of Funds (See Instructions)  AF	
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)  <input type="radio"/>	
6.	Citizenship or Place of Organization  Delaware	
Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power  0
	8.	Shared Voting Power  3,142,580
	9.	Sole Dispositive Power

Edgar Filing: MIRAGEN THERAPEUTICS, INC. - Form SC 13D

		0
	10.	Shared Dispositive Power
		3,142,580
11.	Aggregate Amount Beneficially Owned by Each Reporting Person	
		3,142,580
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)	
		0
13.	Percent of Class Represented by Amount in Row (11)	
		14.8%*
14.	Type of Reporting Person (See Instructions)	
		PN

\* Calculated based upon the approximately 21.3 million shares of the common stock reported by the Issuer to be issued and outstanding as of February 13, 2017, in its Current Report on Form 8-K, as filed with the Securities and Exchange Commission on February 13, 2017.

1.	Names of Reporting Persons.  I.R.S. Identification Nos. of above persons (entities only)  <b>ATLAS VENTURE ASSOCIATES VII, INC.</b>	
2.	Check the Appropriate Box if a Member of a Group (See Instructions)  (a) <input type="radio"/> (b) <input checked="" type="radio"/>	
3.	SEC Use Only	
4.	Source of Funds (See Instructions)  AF	
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)  <input type="radio"/>	
6.	Citizenship or Place of Organization  Delaware	
Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power  0
	8.	Shared Voting Power  3,142,580
	9.	Sole Dispositive Power

Edgar Filing: MIRAGEN THERAPEUTICS, INC. - Form SC 13D

		0
	10.	Shared Dispositive Power
		3,142,580
11.	Aggregate Amount Beneficially Owned by Each Reporting Person	
		3,142,580
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)	
		0
13.	Percent of Class Represented by Amount in Row (11)	
		14.8%*
14.	Type of Reporting Person (See Instructions)	
		CO

\* Calculated based upon the approximately 21.3 million shares of the common stock reported by the Issuer to be issued and outstanding as of February 13, 2017, in its Current Report on Form 8-K, as filed with the Securities and Exchange Commission on February 13, 2017.



**ITEM 1. SECURITY AND ISSUER.**

This Statement on Schedule 13D (this Schedule 13D) relates to shares of common stock (the Common Stock), par value \$0.001 per share (the Shares), of Miragen Therapeutics, Inc., a Delaware corporation (the Issuer). The address of the Issuer's principal executive office is 6200 Lookout Road, Boulder, Colorado 80301. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

**ITEM 2. IDENTITY AND BACKGROUND.**

**Item 2 (a) (c).** This Schedule 13D is being filed by the following persons: Atlas Venture Fund VII, L.P., a Delaware limited partnership (Atlas VII), Atlas Venture Associates VII, L.P., a Delaware limited partnership (AVA VII LP) and Atlas Venture Associates VII, Inc., a Delaware corporation (AVA VII Inc.). Atlas VII, AVA VII LP and AVA VII Inc. are sometimes individually referred to herein as a Reporting Person and collectively as the Reporting Persons.

AVA VII LP is the sole general partner of Atlas VII, and AVA VII Inc. is the sole general partner of AVA VII LP.

The principal business of each of the Reporting Persons is venture capital investing. The business address and principal executive offices of each of the Reporting Persons are 25 First Street, Suite 303, Cambridge, MA 02141.

The Shares to which this Schedule 13D relates are owned directly by Atlas VII.

**Item 2 (d) (e).** During the last five years, none of the Reporting Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors), or has been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.

**Item 2 (f).** Atlas VII and AVA VII LP is each a limited partnership formed under the laws of the State of Delaware. AVA VII Inc. is a corporation formed under the laws of the State of Delaware.

**ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.**

The information set forth in Item 4 hereof is hereby incorporated by reference into this Item 3, as applicable.

**ITEM 4. PURPOSE OF TRANSACTION.**

**Merger Agreement**

As more fully described in the Agreement and Plan of Merger and Reorganization, dated as of October 31, 2016 (the **Merger Agreement**), by and among the Issuer, Signal Merger Sub, Inc. and the corporation then known as Miragen Therapeutics, Inc. (**Old Miragen**), the shares of common stock of Old Miragen were converted into the right to receive shares of the Issuer in the merger contemplated by the Merger Agreement (the **Merger**). Pursuant to the terms of the Merger Agreement, each share of Old Miragen common stock was converted into the right to receive 0.7031 Shares of the Issuer's Common Stock. Immediately prior to the consummation of the merger, Atlas VII held an aggregate of 4,469,607 shares of common stock of Old Miragen, which in turn had represented 83,250 shares of common stock of Old Miragen held by Atlas VII plus shares of common stock of Old Miragen issued upon the conversion of 2,661,454 shares of Series A preferred stock of Old Miragen, 479,401 shares of Series B preferred stock of Old Miragen and 1,245,502 shares of Series C preferred stock of Old Miragen held by Atlas VII. Immediately prior to the effective time of the merger, each share of Old Miragen preferred stock converted into one share of Old Miragen's common stock. As a result of the Merger, the 4,469,607 shares of Old Miragen common stock held by Atlas VII immediately prior to the Merger converted into the right to receive 3,142,580 Shares.

Atlas VII acquired the shares of common stock of Old Miragen as investment in its ordinary course of business.

**Lock-Up Agreement**

---

In connection with the Merger, and in order to induce the parties to close the Merger, certain officers, directors and securityholders of Old Miragen (each, a **Securityholder**) entered into a lock-up agreement, dated October 31, 2016 (the **Lock-Up Agreement**), with Old Miragen that provided that from and after the date thereof until the earlier to occur of (a) 180 days after the Closing Date (as defined in the Merger Agreement) or (b) such date and time as the Merger Agreement shall be terminated (the **Lock-Up Period**), such Securityholders would not, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, any of the Issuer's securities or shares of Signal common stock, including, as applicable, Shares received in the Merger and issuable upon exercise of certain warrants and options.

In connection with the foregoing, and as may be appropriate from time to time, each of the Reporting Persons may consider the feasibility and advisability of various alternative courses of action with respect to its investment in the Issuer, including, without limitation: (a) the acquisition or disposition by the Reporting Persons of Shares, including through derivative transactions which may include security-based swaps and short sales; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) changes in the present board of directors or management of the Issuer; (e) a material change in the present capitalization or dividend policy of the Issuer; (f) other material changes in the Issuer's business or corporate structure; (g) changes in the Issuer's articles of incorporation or bylaws or other actions that may impede the acquisition of control of the Issuer by any person; (h) causing any class of the Issuer's securities to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) causing a class of equity securities of the Issuer to become eligible for termination of registration pursuant to Section 12 of the Exchange Act; or (j) any action similar to those enumerated above. Except as described in Item 6 and this Item 4 and any plans or proposals that may from time to time be discussed or considered by the directors of the Issuer, including Bruce Booth, who is also a director of AVA VII Inc., in their fiduciary capacities as directors of the Issuer, the Reporting Persons do not currently have any plans or proposals that relate to or would result in any of the actions specified in clause (a) through (j) of this paragraph.

The Reporting Persons reserve the right, based on all relevant factors and subject to applicable law or other restrictions, at any time and from time to time, to acquire additional Shares, dispose of some or all of the Shares, in each case in open market or private transactions, block sales or otherwise, and review or reconsider their position, change their purpose, take other actions (including actions that could involve one or more of the types of transactions or have one or more of the results described in clauses (a) through (j) of the foregoing paragraph of this Item 4) or formulate and implement plans or proposals with respect to any of the foregoing. Except as set forth in this Schedule 13D, no contract, arrangement, relationship or understanding (either oral or written) exists among the Reporting Persons as to the acquisition, disposition, voting or holding of Shares.

The Reporting Persons intend to review their investment in the Issuer from time to time on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's stock in particular, as well as other developments.

#### **ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.**

(a) and (b) As of February 13, 2017, Atlas VII beneficially owned and had shared voting and dispositive power with respect to 3,142,580 Shares, representing approximately 14.8% of the approximately 21.3 million shares of common stock issued and outstanding as of February 13, 2017 as reported in the Issuer's Current Report on Form 8-K, as filed with the Securities and Exchange Commission on February 13, 2017.

Edgar Filing: MIRAGEN THERAPEUTICS, INC. - Form SC 13D

As of February 13, 2017, AVA VII LP, by virtue of its position as general partner of Atlas VII, may be deemed to beneficially own and had shared voting and dispositive power with respect to 3,142,580 Shares, representing approximately 14.8% of the approximately 21.3 million shares of common stock issued and outstanding as of February 13, 2017 as reported in the Issuer's Current Report on Form 8-K, as filed with the Securities and Exchange Commission on February 13, 2017.

---

As of February 13, 2017, AVA VII Inc., by virtue of its position as general partner of AVA VII LP, may be deemed to beneficially own and had shared voting and dispositive power with respect to 3,142,580 Shares, representing approximately 14.8% of the approximately 21.3 million shares of common stock issued and outstanding as of February 13, 2017 as reported in the Issuer's Current Report on Form 8-K, as filed with the Securities and Exchange Commission on February 13, 2017.

(c) Information with respect to all transactions in the Shares beneficially owned by the Reporting Persons that were effected during the past sixty days is set forth in Item 4 and incorporated herein by reference.

(d) Not applicable.

(e) Not applicable.

**ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.**

The information set forth in Item 4 hereof is hereby incorporated by reference into this Item 6. Except as referenced above or described in Item 4 hereof, there are no contracts, arrangements, understandings or relationships among the Reporting Persons or between such Reporting Persons and any other person with respect to any securities of the Issuer.

**ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.**

Exhibit 99.1 Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended

Exhibit 99.2 Form of Lock-Up Agreement, dated as of October 31, 2016, by and between Miragen Therapeutics, Inc. and Atlas Venture Fund VII, L.P.

**SIGNATURES**

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

Dated: February 23, 2017

**ATLAS VENTURE FUND VII, L.P.**

By: Atlas Venture Associates VII, L.P., its general partner  
By: Atlas Venture Associates VII, Inc., its general partner

By: /s/ Frank Castellucci  
Name: Frank Castellucci  
Title: Secretary

**ATLAS VENTURE ASSOCIATES VII, L.P.**

By: Atlas Venture Associates VII, Inc., its general partner

By: /s/ Frank Castellucci  
Name: Frank Castellucci  
Title: Secretary

**ATLAS VENTURE ASSOCIATES VII, INC.**

By: /s/ Frank Castellucci  
Name: Frank Castellucci  
Title: Secretary

---

EXHIBIT INDEX

Exhibit No.	Description
99.1	Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended
99.2	Form of Lock-Up Agreement, dated as of October 31, 2016, by and between Miragen Therapeutics, Inc. and Atlas Venture Fund VII, L.P.

---